| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/02/2006 | US20060024298 Optimized Fc variants |
| 02/02/2006 | US20060024297 Tie complex binding proteins |
| 02/02/2006 | US20060024296 As an antagonist that inhibits immunoglobulin secretion; autoimmune disorders; antiproliferative , anticarcinogenic and antiarthritic agents; inflammatory bowel disease |
| 02/02/2006 | US20060024295 Method for treating lupus |
| 02/02/2006 | US20060024294 Compositions for prevention and treatment of infections caused by parasites in animals |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024292 Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
| 02/02/2006 | US20060024291 Protocadherin materials and methods |
| 02/02/2006 | US20060024290 prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics |
| 02/02/2006 | US20060024285 Carcinogen detoxification composition and method |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | US20060024233 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 02/02/2006 | US20060024232 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| 02/02/2006 | US20060024231 Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
| 02/02/2006 | CA2579753A1 Non-integrative and non-replicative lentivirus, preparation and uses thereof |
| 02/02/2006 | CA2575683A1 Chn-1/chip-antagonists for the treatment of muscular diseases |
| 02/02/2006 | CA2575604A1 Methods for detecting and treating autoimmune disorders |
| 02/02/2006 | CA2575356A1 Use of llt1 and/or cd161 for modulating the activity of cells of the immune system |
| 02/02/2006 | CA2575218A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 02/02/2006 | CA2573359A1 Method of treating sjogren's syndrome |
| 02/02/2006 | CA2573018A1 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 02/02/2006 | CA2571261A1 Safer attenuated virus vaccines with missing or diminished latency of infection |
| 02/01/2006 | EP1621635A2 Self-assembling recombinant HP16 papillomavirus capsid proteins |
| 02/01/2006 | EP1621627A2 Use of porcine gala (1,3) galactosyl transferase in xenograft therapies |
| 02/01/2006 | EP1621623A2 BASB029 polynucleotide(s) and polypeptides from Neisseria meningitis |
| 02/01/2006 | EP1621622A1 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof |
| 02/01/2006 | EP1621555A1 Immunogen, composition for immunological use, and method of producing antibody using the same |
| 02/01/2006 | EP1621554A1 Immunoglobulins devoid of light chains |
| 02/01/2006 | EP1621553A1 Antibodies that inhibit transport activity of peptide transporters |
| 02/01/2006 | EP1621551A1 Use of LLT1 and/or CD161 for modulating the activity of cells of the immune system |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621547A1 C of malarial pre-erythrocytic stage polypeptide molecules and lipids |
| 02/01/2006 | EP1621209A2 Vaccines based on domains of chimeric immunoglobulin E peptides |
| 02/01/2006 | EP1621208A1 DNA vaccination for treatment of autoimmune disease |
| 02/01/2006 | EP1621206A1 Chimeric cytokines and uses thereof |
| 02/01/2006 | EP1621203A1 RNAIII-inhibiting peptides for treating HIV infection |
| 02/01/2006 | EP1621195A2 The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 02/01/2006 | EP1621077A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 02/01/2006 | EP1620554A2 Recombinant fel d 1 allergen |
| 02/01/2006 | EP1620550A2 Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620461A2 Group 1 mite polypeptide variants |
| 02/01/2006 | EP1620128A1 Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| 02/01/2006 | EP1620127A2 Methods for treating taxol-induced gut disorder |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620125A2 Tolerance to graft following thymic reactivation |
| 02/01/2006 | EP1620070A2 Toll-like receptor 9 effector agents and uses thereof |
| 02/01/2006 | EP1619992A2 Expressed genes that define the osteoclast phenotype |
| 02/01/2006 | EP1619952A2 Tolerance to graft prior to thymic regeneration |
| 02/01/2006 | EP1466622A4 Medicinal agent and method for curing diseases accompanied with vascular dystonia |
| 02/01/2006 | EP1200479B1 Multiple cytokine-antibody complexes |
| 02/01/2006 | EP1133315B1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 02/01/2006 | EP1066052B1 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 02/01/2006 | EP1064402B1 Antisense modulation of lfa-3 |
| 02/01/2006 | EP1047448B1 Dna vaccines against tick-borne flaviviruses |
| 02/01/2006 | EP1028750B1 Method for preparing multivalent vaccines |
| 02/01/2006 | EP0922056B1 New fibrinogen binding protein originating from coagulase-negative staphylococcus |
| 02/01/2006 | EP0835313B1 Omp26 antigen from haemophilus influenzae |
| 02/01/2006 | CN1729202A Targeting single epitopes |
| 02/01/2006 | CN1729013A Broad spectrum anti-viral therapeutics and prophylaxis |
| 02/01/2006 | CN1727486A cDNA library of differential expression gene in blood lymphocytes of SARS rehabilitated persons |
| 02/01/2006 | CN1727362A Preparation and application of vaccine for curing tumor in positive carcino-embryonic antigen |
| 02/01/2006 | CN1727359A Compound from catarrh mollase bacterial |
| 02/01/2006 | CN1239701C Humanised antibodies to epidermal growth factor receptor |
| 02/01/2006 | CN1239697C Large brill rhabdo virus toxic strain and its preparation method and application |
| 02/01/2006 | CN1239696C Lefteye flounder lymph tumour virus toxic strain, its preparation method and application |
| 02/01/2006 | CN1239518C Membrane protein polypeptide having pre-B cell growth-supporting ability and gene thereof |
| 01/31/2006 | US6992176 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| 01/31/2006 | US6992170 Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin |
| 01/31/2006 | US6991936 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/31/2006 | US6991929 Hepatitis A vaccines |
| 01/31/2006 | US6991921 Hyaluronan synthase gene and uses thereof |
| 01/31/2006 | US6991911 for detection of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA) anibody production; drug screening; haptens; immunogens |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | US6991797 Immunogenic polypeptides derived from the short time culture filtrate of microbacterium tuberculosis; useful for the vaccination against infections caused by virulent Mycobacterium |
| 01/31/2006 | US6991796 Platlet glycoprotein IBα fusion polypeptides and methods of use thereof |
| 01/31/2006 | US6991795 fusing nucleic acid sequence encoding peptide or protein to be delivered to a modified papillomavirus L2 gene to create a fusion protein gene, expressing gene to form fusion protein, forming virus-like particle, delivering to cell |
| 01/31/2006 | US6991794 FRIL family of factors and nucleic acids encoding the same; use as therapeutics for alleviating and/or reducing the hematopoietic progenitor cell-depleting activity of many cancer therapeutics |
| 01/31/2006 | US6991793 novel live vaccines for control of F. columnare in channel catfish comprising one or more rifampicin resistant mutants of F. columnare, created by multiple passaging of the native isolate on increasing concentrations of rifampicin |
| 01/31/2006 | US6991792 Genetically engineered vaccinia virus fror use in the prevention of diabetes |
| 01/31/2006 | US6991791 Administering anti- human tumor necrosis factor- alpha (TNF alpha) monoclonal antibody, or a TNF binding fragment for therapy of neurodegenerative disease in a human |
| 01/31/2006 | US6991790 administering sodium chloride-free pharmaceutical formulation comprising antibody that binds CD20, antibody not subjected to prior lyophilization, acetate buffer from pH 4.8- 5.5, surfactant and polyol; treatment of lymphomas, strokes, shock |
| 01/31/2006 | US6991789 modulating fusion between a lysosome and an endosome that carries the toxin in the cell; locally co-administering a toxin and a lysosome-endosome fusion inhibitor to a group of muscles of the patient in need thereof |
| 01/31/2006 | US6991779 Biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres, TECHNOSPHEREs tm ) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals |
| 01/26/2006 | WO2006010165A2 Compositions for multi-step delivery of hot-spots radiation to cancer cells |
| 01/26/2006 | WO2006010106A2 Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| 01/26/2006 | WO2006009919A2 Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
| 01/26/2006 | WO2006009843A2 Negative regulation of hypoxia inducible factor 1 by os-9 |
| 01/26/2006 | WO2006009809A2 Vegf inhibitors for the treatment of malignant pleural effusion |
| 01/26/2006 | WO2006009764A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
| 01/26/2006 | WO2006009682A2 Glue compositions for lung volume reduction |
| 01/26/2006 | WO2006009533A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | WO2006009501A1 Prevention of allergy in children |
| 01/26/2006 | WO2006009309A1 Galectin 9-binding protein factor |
| 01/26/2006 | WO2006009114A1 Il-18 receptor antagonist and pharmaceutical composition containing the antagonist |
| 01/26/2006 | WO2006008881A1 Peroral vaccine carrier system |
| 01/26/2006 | WO2006008504A1 Stable compositions containing outer membrane vesicles, methods of manufacturing |
| 01/26/2006 | WO2006008154A1 mRNA MIXTURE FOR VACCINATING AGAINST TUMORAL DISEASES |
| 01/26/2006 | WO2006008076A2 Methods and agents stimulating the immune response |
| 01/26/2006 | WO2006007854A1 Gus3 neuropeptides for regulating hypothalamic function |